Royalty Pharma: Q4 Earnings Snapshot

SelfRugger · 2026-02-23T19:24:32+00:00

Royalty Pharma reported Q4 net income of $214 million, or 38 cents per share, exceeding expectations. Annual profit was $771 million on revenue of $3.25 billion. The company forecasts 2026 revenue between $3.28 billion and $3.43 billion.

SelfRugger

2026-02-23 19:24:32

Abstract generation in progress

Royalty Pharma: Q4 Earnings Snapshot

Associated Press Finance

Wed, February 11, 2026 at 9:32 PM GMT+9 1 min read

In this article:

RPRX

+0.36%

NEW YORK (AP) — NEW YORK (AP) — Royalty Pharma (RPRX) on Wednesday reported fourth-quarter net income of $214 million.

The New York-based company said it had net income of 38 cents per share. Earnings, adjusted for non-recurring costs, came to $1.46 per share.

The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.33 per share.

The company posted revenue of $622 million in the period. Its adjusted revenue was $874 million.

For the year, the company reported profit of $771 million, or $1.37 per share. Revenue was reported as $3.25 billion.

Royalty Pharma expects full-year revenue in the range of $3.28 billion to $3.43 billion.

This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on RPRX at

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.